Dr. Wei-Wu He
you, on near-term our Q&A and quarter with CASI's not any general results financial focusing That session the quarter financial are the programs lead conference remarks. welcome business by covered will a Good everyone, update Thank first and call call. during we said, happy update, to milestones I morning, followed in and questions our Cynthia. begin answer highlights. first our to
the financial our for of first of details contains results release press XXXX. quarter Our
drug, continued a There's I in across that all will continue call, EVOMELA, are company. made preparation highlights for financial our is marketing our to that team Let in of our start With team extremely medical the it CNCTXX. for well commercial would going the poised I'm very costs biopharmaceutical Revenues our financially building financial mind sharing from performance. with leading their and in with next of first commercial proud of in me later pleased the preface to I progress down. begin by strong session in my activities launch dedication we my first no the our our have that course experience, address but saying we and premarketing are this focus. and we our by on optimism doubt and commercial functions quarter. increase drug, the
delivering Beyond will to patients. and that, traction launching life-saving we of our continue drugs
our While continuing well with forward progress move as later-stage we our pipeline our additional continue we with to and to as commercial assets, company. product to grow pursue will assets make
fits We eye. entrepreneurial us development the our We population at core in China's competency patient in clinical development, global look in are products that allowing opportunities with business and drug interested to China. leverage large development an
partners' we look we our not only an asset's potential, but at Specifically, potential. fundamental also development look global at investment
our pipeline to a of in-license We investment includes This equity. and also Our our partnerships. the enhances CAR-T, one, experience in on asset our investing partners is our additional this also shareholders core capture collaboration; management value. of approach, CDXX our CB-XXXX all approach one both development business together, deepens to in-license deep partners provides our and our in reflects continue investment trust. anti-CDXX build our opportunity we upside component the our approach having of gives CID-XXX, additional effective this expertise potential our this and drug executive and in partner. and greatly With at an jointly approach and used medicine biotech global in our It believe shareholders and return time. in typically of inhibitor. This collaboration our that developing investment. will our asset our VCP/pXX an venture development of our developing style confidence We layer We two, while in conviction signals proven believe execution has venture additional with recently, assets, dual most cross-cultural in BI-XXXX,
EVOMELA, We quarter. increase million a will quarter, specifically now the more We a recorded product revenue for ago EVOMELA from our address first year commercial and XX% pipeline. of $X.X our
the full targeting over XXXX than For are year much revenue, greater XXXX. we growth XX%
multiple as As the patients you it available commercially China. in recall, cell for EVOMELA China is will approved EVOMELA prior is stem transplantation high-dose injectable to melphalan of form only in use treatment conditioning a hematopoietic And in were protection multiple year with a cell at into stem proprietary per entry setting. XXXX. is least in transplant is to market, only not just formulation treatment Chinese an the patent myeloma EVOMELA's XXX Prior until melphalan, conducted of it with average myeloma.
dosed more than we in in alone, the meet launched we study awareness with In our adaptation patients post-marketing in The CASI more over XXXX, over closely X,XXX KOLs expedite first with is are in phase. has follow-up expectation our of were EVOMELA's China quarter August for market growth X Chinese quarter XX% that completed worked treated and we EVOMELA. and XXXX, XXXX, well to way X,XXX EVOMELA drive in dosed Following In the patients. the accrual than of -- market. XXXX. And on to
data I to enrolling Phase of Juventas of sales to current our China. marketing trials Through specialists The NNPA its medical and B-NHL registration designation So B-ALL. far, of partner, our asset is also with completed on our With in next ongoing as therapy studies the studies, asset. B-NHL by first both granted II studies are thoroughly CDXX CNCTXX we now The than CDXX breakthrough CAR-T and based last B-NHL just and commercial launch consistent year not products commercial and been the use, to data. with EVOMELA. They China. Phase ready currently make EVOMELA, hematology stand ready more such we based our I published regard launch built to Phase our in team Juventas, continues China the with initial EVOMELA commercial product have of in commercialization, expand additional B-ALL CAR-T, seeing in substantially a and with has progress excellent have B-ALL been XX but for tested
for are Juventas file and is XXXX. end NDA to to the the of we see an to preparations CNCTXX. by make We very starting with track on NNPA of activities, encouraging launch continue
in we therapy CDXX which foreign it distinguishes As manufactured of therapies products CMC patients be in no previously approved will currently greatly manufactured, where higher and for stated, CNCTXX significantly an than certain China. outside CAR-T other are believe domestic. of China, China, innovative we and ex-China cost XX locally CAR-T priced. have CDXX therapies is outside subject point price and Drug products. there manufactured CNCTXX still or premium issue can to for China the goods, developed are and are developed, be Comparable that particularly developed pricing of making from
address added pipeline across our considerable Difficulty] pipeline and will I key tactically our and most updates that our provide have other progress on assets. I'm current Next, additional recent have made we pleased [Technical
